Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIlogy-4: JNJ-79635322 versus teclistamab in relapsed or refractory multiple myeloma
jRCT2031250731Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing JNJ-79635322 with Teclistamab (2 arms). Primary endpoints: Overall response and Progression-free survival. Started Mar 2026; status: recruiting.
02
Drugs
ramantamigteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031250731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250731.